We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+5.7%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$379M
AUM Growth
+$697K
Cap. Flow
-$7.42M
Cap. Flow %
-1.96%
Top 10 Hldgs %
54.1%
Holding
70
New
14
Increased
14
Reduced
8
Closed
4

Top Buys

Rank Stock Value
1
SUPN icon
Supernus Pharmaceuticals
SUPN
+$6.21M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$5.89M
3
HRMY icon
Harmony Biosciences
HRMY
+$4.98M
4
INCY icon
Incyte
INCY
+$4.91M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$4.17M

Top Sells

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$18.3M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$14.3M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$8.11M
4
ILMN icon
Illumina
ILMN
+$6.26M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$5.95M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALKS icon
51
Alkermes
ALKS
$8.2B
$1.1M 0.29%
+45,000
New +$1M
AXSM icon
52
Axsome Therapeutics
AXSM
$10.8B
$944K 0.25%
14,000
– –
ORIC icon
53
Oric Pharmaceuticals
ORIC
$1.42B
$938K 0.25%
53,000
– –
FOLD
54
DELISTED
Amicus Therapeutics
FOLD
$912K 0.24%
94,600
– –
GBT
55
DELISTED
Global Blood Therapeutics, Inc.
GBT
$763K 0.2%
21,800
– –
GMDA
56
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$682K 0.18%
107,000
– –
IMVT icon
57
Immunovant
IMVT
$9.05B
$634K 0.17%
+60,000
New +$838K
ARDX icon
58
Ardelyx
ARDX
$986M
$591K 0.16%
+78,000
New +$577K
BDTX icon
59
Black Diamond Therapeutics
BDTX
$130M
$535K 0.14%
+44,000
New +$870K
KYNB
60
Kyntra Bio
KYNB
$32.4M
$525K 0.14%
788
– –
NBP
61
NovaBridge Biosciences American Depositary Shares
NBP
$219M
$503K 0.13%
6,000
-29,000
-83% -$1.91M
XENE icon
62
Xenon Pharmaceuticals
XENE
$6B
$474K 0.13%
+25,500
New +$470K
BLUE
63
DELISTED
bluebird bio
BLUE
$351K 0.09%
849
– –
TVTX icon
64
Travere Therapeutics
TVTX
$6.36B
$292K 0.08%
20,000
– –
ANAB icon
65
AnaptysBio
ANAB
$1.7B
$259K 0.07%
10,000
– –
ESPR
66
DELISTED
Esperion Therapeutics
ESPR
$201K 0.05%
9,500
– –
ACAD icon
67
Acadia Pharmaceuticals
ACAD
$5.12B
– –
-59,514
Closed -$1.53M
CRSP icon
68
CRISPR Therapeutics
CRSP
$5.74B
– –
-22,000
Closed -$2.68M
ILMN icon
69
Illumina
ILMN
$34.4B
– –
-16,756
Closed -$6.26M
SAGE
70
DELISTED
Sage Therapeutics
SAGE
– –
-21,500
Closed -$1.61M
1 2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q2 2021 Portfolio in Review

As of Q2 2021, International Biotechnology Trust held 70 positions worth $379M, up 0.18% from $378M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

International Biotechnology Trust's Q2 2021 filing shows 14 new, 14 increased, 8 reduced and 4 closed positions. Its largest new stake was Supernus Pharmaceuticals: 202,436 shares worth $6.23M. The largest sale was Exelixis, an estimated $18.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • International Biotechnology Trust's largest Q2 2021 buy was Supernus Pharmaceuticals: 202,436 shares worth $6.23M.
  • International Biotechnology Trust added most to Alnylam Pharmaceuticals in Q2 2021, an estimated $5.89M increase.
  • International Biotechnology Trust's biggest Q2 2021 reduction was Exelixis, cutting an estimated $18.3M.
  • International Biotechnology Trust fully exited Illumina in Q2 2021, selling an estimated $6.26M.
  • International Biotechnology Trust's ten largest holdings make up 54% of its $379M portfolio in Q2 2021.
  • International Biotechnology Trust opened 14 new positions and closed 4 in Q2 2021.
  • International Biotechnology Trust's portfolio value rose 0.18% quarter-over-quarter to $379M.

Based on International Biotechnology Trust's 13F filing for Q2 2021, filed 11 Aug 2021.